Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Finds Sanofi and Celgene DTC Ads are Misleading

XTALKS VITALS NEWS

DTC Advertising

The FDA's Office of Prescription Drug Promotion (OPDP) ordered Sanofi and Celgene to discontinue the ads, in two separate letters to the drugmakers.

Share this!

December 16, 2016 | by Sarah Hand, M.Sc.

The US Food and Drug Administration (FDA) has identified two direct-to-consumer (DTC) ads for prescription drugs, which it believes misleads consumers in regards to the safety of the medications. The FDA's Office of Prescription Drug Promotion (OPDP) ordered Sanofi and Celgene to discontinue the ads, in two separate letters to the drugmakers.

Sanofi’s ad was in promotion of its diabetes drug, Toujeo (insulin glargine), and showed a man dancing to an upbeat song while a narrator disclosed the contra-indications and potential side effects of the drug. The FDA’s OPDP took issue with the ad’s rapid camera cuts and “attention-grabbing” visuals which could distract the viewer from the important risk information.

“The overall effect undermines the communication of the important risk information and thereby misleadingly minimizes the risks associated with the use of Toujeo,” said the FDA’s letter to Sanofi. “The presentation in the video is especially problematic from a public health perspective given the serious and potentially life-threatening risks associated with the drug.”



Celgene’s ad for its severe plaque psoriasis drug, Otzela (apremilast), was similarly fast-paced, featuring four successive scenes while the narrator reads the risk information. In this case, the visuals were deemed to be too distracting, thereby minimizing the risks of taking the medication.

“The presentation of these compelling and attention-grabbing visuals and SUPERs, all of which are unrelated to the risk message, in addition to the frequent scene changes and the other competing modalities such as the musical interjections, compete for the consumers’ attention,” said the FDA’s letter to Celgene. “As a result, it is difficult for consumers to adequately process and comprehend the risk information.”

Since January, the OPDP has only issued five other letters like these to drugmakers. Still, they serve as a timely reminder that DTC ads must follow strict guidelines to ensure that benefit/risk information is presented equally.


Keywords: FDA, DTC Advertising, Risk Information


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.